The Therapeutic Trip of Melatonin Eye Drops: From the Ocular Surface to the Retina

• Published in: Pharmaceuticals (Basel, Switzerland) Vol. 17; no. 4; p. 441
• Main Authors: Rusciano, Dario, Russo, Cristina
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01-04-2024; MDPI
• Subjects: Antioxidants; Aqueous solutions; Care and treatment; cataract; Contact lenses; Dosage and administration; drug delivery; Drug delivery systems; dry eye; Eye diseases; glaucoma; Hypertension; Lipids; Melatonin; Metabolism; Metabolites; Nanoparticles; nanotech formulation; Ophthalmic solutions; Physiology; Retina; Review; Italy; cataract; glaucoma; myopia; drug delivery; nanotech formulation; diabetic retinopathy; dry eye; melatonin; uveitis; macular degeneration
• ISSN: 1424-8247; 1424-8247
• DOI: 10.3390/ph17040441

Melatonin is a ubiquitous molecule found in living organisms, ranging from bacteria to plants and mammals. It possesses various properties, partly due to its robust antioxidant nature and partly owed to its specific interaction with melatonin receptors present in almost all tissues. Melatonin regulates different physiological functions and contributes to the homeostasis of the entire organism. In the human eye, a small amount of melatonin is also present, produced by cells in the anterior segment and the posterior pole, including the retina. In the eye, melatonin may provide antioxidant protection along with regulating physiological functions of ocular tissues, including intraocular pressure (IOP). Therefore, it is conceivable that the exogenous topical administration of sufficiently high amounts of melatonin to the eye could be beneficial in several instances: for the treatment of eye pathologies like glaucoma, due to the IOP-lowering and neuroprotection effects of melatonin; for the prevention of other dysfunctions, such as dry eye and refractive defects (cataract and myopia) mainly due to its antioxidant properties; for diabetic retinopathy due to its metabolic influence and neuroprotective effects; for macular degeneration due to the antioxidant and neuroprotective properties; and for uveitis, mostly owing to anti-inflammatory and immunomodulatory properties. This paper reviews the scientific evidence supporting the use of melatonin in different ocular districts. Moreover, it provides data suggesting that the topical administration of melatonin as eye drops is a real possibility, utilizing nanotechnological formulations that could improve its solubility and permeation through the eye. This way, its distribution and concentration in different ocular tissues may support its pleiotropic therapeutic effects.